<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>3</volume><submitter>Majer IM</submitter><pubmed_abstract>Treatment with long-acting injectable (LAI) antipsychotic medication is an important element of relapse prevention in schizophrenia. Recently, the intramuscular once-monthly formulation of aripiprazole received marketing approval in Europe and the United States for schizophrenia. This study aimed to compare aripiprazole once-monthly with other LAI antipsychotics in terms of efficacy, tolerability, and safety. A systematic literature review was conducted to identify relevant double-blind randomized clinical trials of LAIs conducted in the maintenance treatment of schizophrenia. MEDLINE, MEDLINE In-Process, Embase, the Cochrane Library, PsycINFO, conference proceedings, clinical trial registries, and the reference lists of key review articles were searched. The literature search covered stud</pubmed_abstract><journal>Journal of market access &amp; health policy</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4802697</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.</pubmed_title><pmcid>PMC4802697</pmcid><pubmed_authors>Beillat M</pubmed_authors><pubmed_authors>Gaughran F</pubmed_authors><pubmed_authors>Treur M</pubmed_authors><pubmed_authors>Sapin C</pubmed_authors><pubmed_authors>Majer IM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.</name><description>Treatment with long-acting injectable (LAI) antipsychotic medication is an important element of relapse prevention in schizophrenia. Recently, the intramuscular once-monthly formulation of aripiprazole received marketing approval in Europe and the United States for schizophrenia. This study aimed to compare aripiprazole once-monthly with other LAI antipsychotics in terms of efficacy, tolerability, and safety. A systematic literature review was conducted to identify relevant double-blind randomized clinical trials of LAIs conducted in the maintenance treatment of schizophrenia. MEDLINE, MEDLINE In-Process, Embase, the Cochrane Library, PsycINFO, conference proceedings, clinical trial registries, and the reference lists of key review articles were searched. The literature search covered stud</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015</publication><modification>2025-04-21T18:34:35.591Z</modification><creation>2019-03-27T03:10:03Z</creation></dates><accession>S-EPMC4802697</accession><cross_references><pubmed>27123183</pubmed><doi>10.3402/jmahp.v3.27208</doi></cross_references></HashMap>